<section class="slide" data-slide-id="S20">
  <div class="label-gold" style="font-size:0.90vw;">CLEAR Outcomes — EtD (GRADE)</div>

  <h2 style="margin-top:0.8vw; margin-bottom: 0.55vw;">
    Do trial à decisão: <span style="color: var(--gold);">EtD</span> no bempedóico
  </h2>

  <div class="lead" style="max-width: 92%; margin-bottom: 1.35vw;">
    Quando o <strong>benefício absoluto</strong> é pequeno, o EtD (valores, acesso, custo) costuma decidir o “sim/ não” na prática.
  </div>

  <div style="display:grid; grid-template-columns: 1.05fr 0.95fr; gap: 2.0vw; flex-grow: 1; align-items: start;">

    <!-- LEFT: o que a evidência entrega -->
    <div class="card" style="padding: 0; overflow: hidden; border: 1px solid rgba(var(--navy-rgb),0.18);">
      <div class="cardHeader" style="display:flex; justify-content:space-between; align-items:center;">
        <span>O que o trial entrega</span>
        <span class="chip chip--navy">MACE‑4</span>
      </div>
      <div class="cardBody" style="padding: 1.25vw 1.35vw;">

        <div style="display:grid; grid-template-columns: 1fr 1fr; gap: 1.05vw; align-items: stretch;">
          <div style="border: 1px solid rgba(var(--blue-rgb),0.24); border-radius: 0.95vw; padding: 1.05vw; background: rgba(var(--blue-rgb),0.06);">
            <div style="font-size: 0.82vw; color: rgba(var(--navy-rgb),0.70); text-transform: uppercase; letter-spacing: 0.08em; font-weight: 900;">Efeito relativo</div>
            <div style="margin-top: 0.35vw; font-family: var(--font-serif); font-size: 3.15vw; font-weight: 800; color: var(--blue); line-height: 1;">HR 0,87</div>
            <div style="margin-top: 0.25vw; font-size: 1.02vw; color: rgba(var(--navy-rgb),0.70);">IC 95%: 0,79–0,96</div>
          </div>

          <div style="border: 1px solid rgba(var(--gold-rgb),0.28); border-radius: 0.95vw; padding: 1.05vw; background: rgba(var(--gold-rgb),0.10);">
            <div style="font-size: 0.82vw; color: rgba(var(--navy-rgb),0.70); text-transform: uppercase; letter-spacing: 0.08em; font-weight: 900;">Benefício absoluto</div>
            <div style="margin-top: 0.35vw; font-family: var(--font-serif); font-size: 2.45vw; font-weight: 800; color: var(--navy); line-height: 1.1;">ARR 1,6%</div>
            <div style="margin-top: 0.25vw; font-size: 1.02vw; color: rgba(var(--navy-rgb),0.70);">11,7% vs 13,3% (mediana 40,6 meses)</div>
          </div>
        </div>

        <div style="margin-top: 1.05vw; display:grid; grid-template-columns: 1fr 1fr; gap: 1.05vw;">
          <div style="border: 1px solid rgba(var(--navy-rgb),0.10); border-radius: 0.95vw; padding: 1.0vw; background: rgba(var(--navy-rgb),0.02);">
            <div style="font-size: 0.82vw; color: var(--muted); text-transform: uppercase; letter-spacing: 0.08em; font-weight: 900;">NNT (aprox.)</div>
            <div style="margin-top: 0.35vw; font-family: var(--font-serif); font-size: 2.65vw; font-weight: 800; color: var(--navy); line-height: 1;">≈ 63</div>
            <div style="margin-top: 0.25vw; font-size: 0.98vw; color: rgba(var(--navy-rgb),0.70);">no período do trial</div>
          </div>
          <div style="border: 1px solid rgba(var(--teal-rgb),0.22); border-radius: 0.95vw; padding: 1.0vw; background: rgba(var(--teal-rgb),0.07);">
            <div style="font-size: 0.82vw; color: var(--muted); text-transform: uppercase; letter-spacing: 0.08em; font-weight: 900;">LDL‑C</div>
            <div style="margin-top: 0.35vw; font-family: var(--font-serif); font-size: 2.65vw; font-weight: 800; color: var(--navy); line-height: 1;">≈ −21 mg/dL</div>
            <div style="margin-top: 0.25vw; font-size: 0.98vw; color: rgba(var(--navy-rgb),0.70);">diferença vs placebo</div>
          </div>
        </div>

        <div class="note" style="margin-top: 1.05vw; border-left-color: var(--gold); background: rgba(var(--gold-rgb),0.10);">
          <p style="margin:0; font-size: 1.03vw; line-height: 1.45; color: var(--navy);">
            <b>Leitura:</b> efeito relativo consistente, mas ganho absoluto pequeno → espaço para o EtD.
          </p>
        </div>

      </div>
    </div>

    <!-- RIGHT: EtD em chunks -->
    <div style="display:flex; flex-direction:column; gap: 1.15vw;">

      <div class="card" style="padding: 0; overflow: hidden; border: 1px solid rgba(var(--gold-rgb),0.26);">
        <div class="cardHeader" style="display:flex; justify-content:space-between; align-items:center;">
          <span>EtD (o que pesa)</span>
          <span class="chip chip--gold">decisão</span>
        </div>
        <div class="cardBody" style="padding: 1.15vw 1.25vw; display:flex; flex-direction:column; gap: 0.85vw;">

          <div style="display:flex; gap: 0.85vw; align-items:flex-start;">
            <span class="iconCircle iconCircle--gold">1</span>
            <div style="font-size: 1.06vw; line-height: 1.45; color: var(--navy);">
              <b>Certeza:</b> RCT começa alto, mas pode cair para <b>moderada</b> se o IC encosta no limiar (imprecisão/MID).
            </div>
          </div>

          <div style="display:flex; gap: 0.85vw; align-items:flex-start;">
            <span class="iconCircle iconCircle--teal">2</span>
            <div style="font-size: 1.06vw; line-height: 1.45; color: var(--navy);">
              <b>Trade‑offs:</b> monitorar eventos adversos relevantes (ex.: ácido úrico/gota) e preferências do paciente.
            </div>
          </div>

          <div style="display:flex; gap: 0.85vw; align-items:flex-start;">
            <span class="iconCircle">3</span>
            <div style="font-size: 1.06vw; line-height: 1.45; color: var(--navy);">
              <b>Viabilidade:</b> VO 1×/dia; no Brasil, acesso (SUS vs privado) tende a ser o gargalo.
            </div>
          </div>

        </div>
      </div>

      <div class="card bg-navy" style="padding: 1.25vw 1.35vw; border: 1px solid rgba(255,255,255,0.14);">
        <div style="font-size: 0.82vw; color: rgba(255,255,255,0.75); text-transform: uppercase; letter-spacing: 0.10em; font-weight: 900;">Tradução para o plantão</div>
        <div style="margin-top: 0.75vw; font-family: var(--font-serif); font-size: 1.55vw; line-height: 1.32; color: rgba(255,255,255,0.94);">
          Se a SAMS é <b>real</b> e o risco é alto: mantenho a <b>maior dose tolerada</b> + adiciono alternativa <b>viável</b> (ezetimiba → PCSK9i / bempedóico).
        </div>
      </div>

    </div>

  </div>

  <div class="ref" style="margin-top:auto; padding-top: 0.9vw; border-top: 1px solid var(--border); left:6%; right:6%; font-size:0.86vw;">
    Fonte: Nissen SE et al. <i>N Engl J Med</i> 2023;388:1353–1364 (CLEAR Outcomes) • GRADE Working Group (EtD) • SBC 2025.
  </div>
</section>
